| abstract |
FIELD: medicine; pharmaceuticals.SUBSTANCE: first object is a pharmaceutical combination for treating cancer, containing inhibitor of MDM2 (6S)-5-(5-chloro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-6-(4-chlorophenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-1-(propan-2-yl)-5,6-dihydropyrrolo[3,4-d]imidazole-4(1H)-one or a pharmaceutically acceptable salt thereof and Bcl2 ABT-199 inhibitor or a pharmaceutically acceptable salt thereof. 2 object is a pharmaceutical composition for treating cancer. 3 and 5 objects—using a pharmaceutical combination or pharmaceutical composition for treating and a method of treating acute myelogenous leukemia. 4—application of a pharmaceutical combination for preparing a drug for treating acute myelogenous leukemia.EFFECT: technical effect consists in higher effectiveness of anticancer therapy combination of (6S)-5-(5-chloro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-6-(4-chlorophenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-1-(propan-2-yl)-5,6-dihydropyrrolo[3,4-d]imidazole-4(1H)-one and ABT-199 in comparison with their application separately.8 cl, 11 tbl, 10 ex, 18 dwg |